SK286399B6 - V podstate nehydratovaná a nehygroskopická alebo iba mierne hygroskopická hydrochloridová soľ 5-[4-[2-(N-metyl-N-(2- pyridyl)amino)etoxy]benzyl]tiazolidín-2,4-diónu, spôsob jej prípravy, farmaceutický prostriedok s jej obsahom a jej použitie - Google Patents

V podstate nehydratovaná a nehygroskopická alebo iba mierne hygroskopická hydrochloridová soľ 5-[4-[2-(N-metyl-N-(2- pyridyl)amino)etoxy]benzyl]tiazolidín-2,4-diónu, spôsob jej prípravy, farmaceutický prostriedok s jej obsahom a jej použitie Download PDF

Info

Publication number
SK286399B6
SK286399B6 SK1330-2002A SK13302002A SK286399B6 SK 286399 B6 SK286399 B6 SK 286399B6 SK 13302002 A SK13302002 A SK 13302002A SK 286399 B6 SK286399 B6 SK 286399B6
Authority
SK
Slovakia
Prior art keywords
pyridyl
ethoxy
benzyl
methyl
amino
Prior art date
Application number
SK1330-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK13302002A3 (sk
Inventor
Andrew Simon Craig
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of SK13302002A3 publication Critical patent/SK13302002A3/sk
Publication of SK286399B6 publication Critical patent/SK286399B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK1330-2002A 2000-03-14 2001-03-14 V podstate nehydratovaná a nehygroskopická alebo iba mierne hygroskopická hydrochloridová soľ 5-[4-[2-(N-metyl-N-(2- pyridyl)amino)etoxy]benzyl]tiazolidín-2,4-diónu, spôsob jej prípravy, farmaceutický prostriedok s jej obsahom a jej použitie SK286399B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0006133.3A GB0006133D0 (en) 2000-03-14 2000-03-14 Novel pharmaceutical
PCT/GB2001/001131 WO2001068646A1 (en) 2000-03-14 2001-03-14 Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Publications (2)

Publication Number Publication Date
SK13302002A3 SK13302002A3 (sk) 2003-02-04
SK286399B6 true SK286399B6 (sk) 2008-09-05

Family

ID=9887600

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1330-2002A SK286399B6 (sk) 2000-03-14 2001-03-14 V podstate nehydratovaná a nehygroskopická alebo iba mierne hygroskopická hydrochloridová soľ 5-[4-[2-(N-metyl-N-(2- pyridyl)amino)etoxy]benzyl]tiazolidín-2,4-diónu, spôsob jej prípravy, farmaceutický prostriedok s jej obsahom a jej použitie

Country Status (30)

Country Link
US (2) US7074811B2 (cs)
EP (1) EP1265893B1 (cs)
JP (1) JP2003527393A (cs)
KR (1) KR100746813B1 (cs)
CN (1) CN100516062C (cs)
AP (1) AP1545A (cs)
AT (1) ATE302202T1 (cs)
AU (1) AU777987B2 (cs)
BG (1) BG65924B1 (cs)
BR (1) BR0108870A (cs)
CA (1) CA2403109A1 (cs)
CZ (1) CZ20023074A3 (cs)
DE (1) DE60112729T2 (cs)
DK (1) DK1265893T3 (cs)
DZ (1) DZ3316A1 (cs)
EA (1) EA005115B1 (cs)
ES (1) ES2243458T3 (cs)
GB (1) GB0006133D0 (cs)
HU (1) HUP0300158A3 (cs)
IL (2) IL151425A0 (cs)
MA (1) MA25658A1 (cs)
MX (1) MXPA02008972A (cs)
NO (1) NO323448B1 (cs)
NZ (1) NZ520910A (cs)
OA (1) OA12229A (cs)
PL (1) PL357283A1 (cs)
SK (1) SK286399B6 (cs)
UA (1) UA73974C2 (cs)
WO (1) WO2001068646A1 (cs)
ZA (1) ZA200207292B (cs)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021865D0 (en) * 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0023971D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
AU2002343050A1 (en) * 2001-11-21 2003-06-10 Smithkline Beecham P.L.C. 5-(4-(2-(n-methyl-n-(2-pyridil) amino) ethoxy) benzyl) thiazolidine-2, 4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active ingredient
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US20060235008A1 (en) 2004-08-19 2006-10-19 Hetero Drugs Limited Novel polymorphs of efavirenz
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US20090076093A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched rosiglitazone
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20110067096A (ko) 2008-09-10 2011-06-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 및 관련 상태를 치료하기 위한 병용 요법
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
US8106111B2 (en) * 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
BR112012012641A2 (pt) 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
KR20190050871A (ko) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US120078A (en) * 1871-10-17 Improvement in revolving flower-stands
US137940A (en) * 1873-04-15 Improvement in elevators
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group P.L.C., Brentford Substituierte Thiazolidindionderivate
GB9413975D0 (en) * 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
ID23372A (id) 1997-06-18 2000-04-20 Smithkline Beecham Plc Pengobatan diabetes dengan tiazolidindion dan metformin
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US6664278B2 (en) * 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9909041D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
GB9909075D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
AR023561A1 (es) 1999-04-23 2002-09-04 Smithkline Beecham Corp Una forma polimorfica del acido maleico de un derivado de tiazolidin-2, 4 diona, una composicion farmaceutica y el uso de dicho polimorfo para lafabricacion de un medicamento
DE60037602T2 (de) 1999-04-23 2009-01-08 Smithkline Beecham P.L.C., Brentford Herstellung einer polymorphen Form eines Thiazolidindionderivates
DZ3164A1 (fr) 1999-04-23 2000-11-02 Smithkline Beecham Plc Nouvel agent pharmaceutique.
HU225919B1 (en) 1999-12-18 2007-12-28 Richter Gedeon Nyrt Thiazolidine-derivatives, process for their preparation pharmaceutical and intermediates
CN1277965A (zh) 2000-06-14 2000-12-27 中国医药研究开发中心 盐酸罗格列酮及其应用
GB0021865D0 (en) 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical

Also Published As

Publication number Publication date
MA25658A1 (fr) 2002-12-31
IL151425A0 (en) 2003-04-10
US20040152901A1 (en) 2004-08-05
MXPA02008972A (es) 2003-02-10
DE60112729T2 (de) 2006-06-08
KR100746813B1 (ko) 2007-08-06
NZ520910A (en) 2004-06-25
US20050267162A1 (en) 2005-12-01
ATE302202T1 (de) 2005-09-15
JP2003527393A (ja) 2003-09-16
EP1265893A1 (en) 2002-12-18
GB0006133D0 (en) 2000-05-03
DZ3316A1 (fr) 2001-09-20
ES2243458T3 (es) 2005-12-01
UA73974C2 (en) 2005-10-17
SK13302002A3 (sk) 2003-02-04
BG107012A (bg) 2003-04-30
BR0108870A (pt) 2002-12-17
CN100516062C (zh) 2009-07-22
HK1052502A1 (en) 2003-09-19
KR20020079998A (ko) 2002-10-21
AP1545A (en) 2006-01-12
PL357283A1 (en) 2004-07-26
CN1358184A (zh) 2002-07-10
AP2002002600A0 (en) 2002-09-30
CA2403109A1 (en) 2001-09-20
OA12229A (en) 2003-11-07
US7074811B2 (en) 2006-07-11
BG65924B1 (bg) 2010-05-31
IL151425A (en) 2009-08-03
HUP0300158A3 (en) 2005-04-28
NO323448B1 (no) 2007-05-07
EA005115B1 (ru) 2004-10-28
CZ20023074A3 (cs) 2003-02-12
EP1265893B1 (en) 2005-08-17
NO20024307L (no) 2002-09-09
AU4084301A (en) 2001-09-24
EA200200975A1 (ru) 2003-02-27
ZA200207292B (en) 2003-05-06
HUP0300158A2 (en) 2003-05-28
WO2001068646A1 (en) 2001-09-20
AU777987B2 (en) 2004-11-11
NO20024307D0 (no) 2002-09-09
DK1265893T3 (da) 2005-11-14
DE60112729D1 (de) 2005-09-22

Similar Documents

Publication Publication Date Title
SK286399B6 (sk) V podstate nehydratovaná a nehygroskopická alebo iba mierne hygroskopická hydrochloridová soľ 5-[4-[2-(N-metyl-N-(2- pyridyl)amino)etoxy]benzyl]tiazolidín-2,4-diónu, spôsob jej prípravy, farmaceutický prostriedok s jej obsahom a jej použitie
SK286422B6 (sk) Hydrát 5-[4-[2-(N-metyl-N-(2- pyridyl)amino)etoxy]benzyl]tiazolidín-2,4-dión maleínanu, spôsob jehovýroby, farmaceutický prípravok s jeho obsahom a jeho použitie
SK286618B6 (sk) Hydrát 5-[4-[2-N-metyl-N-(2- pyridyl)amino)etoxy]benzyl]tiazolidín-2,4-dión maleínanu, spôsob jeho výroby, farmaceutický prípravok s jeho obsahom a jeho použitie
US20070191435A1 (en) Hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US20040082620A1 (en) 5'-4-'2-(n-methyl-n-(2-pyridyl)amino)ethoxy!benzyl!thiazolidine-2, 4-dione mesylate salt
US20040048899A1 (en) Tartrate salts of thiazollidnedione derivative
US20070185167A1 (en) Sodium salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US20040014791A1 (en) Thiazolidinedione derivative and its use as antidiabetic
US20040014790A1 (en) Tartrate salt of thiazolidinedione derivative
WO2003050113A1 (en) Hydrogensulfate salt of 5-'4-'2-(n-methyl-n-(2-pyridyl)amino)ethoxy!benzyl!thia zolidine-2,4-dione
SK1452003A3 (en) Tartrate salts of thiazolidinedione derivative
EP1325000B1 (en) A thiazolidinedione derivative and its use as antidiabetic
SK17152002A3 (sk) Hydrojodid 5-[4-[2-(N-metyl-N-(2-pyridyl)amíno)etoxy]- benzyl]tiazolidín-2,4-diónu ako liečivo
US20040087629A1 (en) Tartrate salts of thiazolidinedione derivative
US20040102485A1 (en) Tartrate salt of thiazolidinedione derivative
US20040029926A1 (en) Thiazolidinone nitrate salt
AU2001292028A1 (en) Sodium salts of 5-'4-'2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione
WO2003050111A1 (en) Toluenesulfonate salts of a thiazolidinedione derivative
HK1106226A (en) Sodium salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
HK1058192B (en) A thiazolidinedione derivative and its use as antidiabetic
HK1105818A (en) A thiazolidinedione derivative and its use as antidiabetic
HK1052502B (en) Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20120314